about
The role and interaction of imprinted genes in human fetal growthA case-control study of maternal periconceptual and pregnancy recreational drug use and fetal malformation using hair analysisPerformance of the neoBona test: a new paired-end massively parallel shotgun sequencing approach for cell-free DNA-based aneuploidy screening.Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y.Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood.A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth.Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, Down's syndrome, preterm delivery and preeclampsia.Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum.A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy.Paternally expressed, imprinted insulin-like growth factor-2 in chorionic villi correlates significantly with birth weight.Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks.ASPRE trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history.Two-stage approach for risk estimation of fetal Trisomy 21 and other aneuploidies using computational intelligence systems.Association of chronic hypertension with birth of small-for-gestational-age neonate.Competing risks model in screening for preeclampsia in twin pregnancies by maternal factors and biomarkers at 11-13 weeks' gestation.Impaired placentation in women with chronic hypertension that develop preeclampsia.Chronic hypertension and adverse pregnancy outcome: a cohort study.Metabolomic determination of pathogenesis of late-onset preeclampsia.Validation of metabolomic models for prediction of early-onset preeclampsia.Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks.First-trimester prediction of macrosomia.Assessment of fetal sex chromosome aneuploidy using directed cell-free DNA analysis.Fetal fraction estimate in twin pregnancies using directed cell-free DNA analysis.Birth weight in live births and stillbirths.Prediction of stillbirth from maternal factors, fetal biometry and uterine artery Doppler at 19-24 weeks.Prediction of stillbirth from maternal demographic and pregnancy characteristics.Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.Combined screening for preeclampsia and small for gestational age at 11-13 weeks.First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.Contribution of method of conception on pregnancy outcome after the 11-13 weeks scan.Maternal hemoglobin at 27-29 weeks' gestation and severity of pre-eclampsia.Maternal serum placental growth factor at 11-13 weeks' gestation and fetal cardiac defects.Maternal age and adverse pregnancy outcome: a cohort study.First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.Prediction of preeclampsia by uterine artery Doppler at 20-24 weeks' gestation.A competing risks model in early screening for preeclampsia.Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.Birthweight with gestation and maternal characteristics in live births and stillbirths.Ultrasonographic prediction of early miscarriage.
P50
Q28083223-2DF1A4CE-62E2-403B-BE32-E93D7B196D26Q28544639-94CCE21A-4002-4BA1-BFBF-5B9072AECA1AQ33578416-9DAE3680-FC94-4691-B341-D791FAE05E7EQ34340985-879832AE-355F-420F-B35A-8DBE6DB6E13CQ34378350-3CAB1C88-82C4-4FF6-8078-AB73C202F599Q34518406-A992A8A7-DDF8-42A7-B657-F99EB476440EQ36604516-87AFF2F1-C085-4390-9590-5973F1263114Q36908093-F57B5E9A-394B-48CB-B67D-0983275BDA99Q37460903-C043CDC1-01CB-468B-A32A-D8BA8650ED19Q37484070-14F3B26B-640F-4B61-B486-6EEED3EF95CCQ37826400-4E3C7B3A-6CDD-4020-9C36-F78FA412DFA9Q38636397-C619185A-331D-4178-A356-BD441356A8FCQ38713985-73C48748-20D8-4B68-9B4C-797439F4898FQ38715807-8B581FCC-C1CD-45D9-A353-2E0C6D05FBFFQ38757227-759914C7-27FE-4BE9-B5AF-AD91C9E6CC09Q38805483-6BF57EE8-4DF2-4103-89C8-8493DEECA137Q38823697-426DD702-96FA-4FC9-A132-834EEE2FCB6BQ38827023-32E9BF1E-73D1-4A7C-9B91-EC99ECD08318Q38990948-EEEB06CE-BDB0-4DA7-99D0-8B4ECFCF1918Q39789690-A672F354-BEA1-4232-832C-F51FE8F428A1Q39843643-C819AD4E-03CF-4E45-9960-BCB94E58262AQ40157604-0EE5EEDB-D7E2-4241-8186-1E4B9D86706EQ40159346-F37B939E-FD93-4A50-B2B8-11D5F4255262Q40472327-FE73B57E-CFA5-4321-B755-7BCDB64F29D2Q40472344-2FE10198-CFD4-49BB-868E-9AB2D595AFC6Q40607300-2CD2A143-CCD6-4641-8A82-6A8DFBE52D52Q40617657-2379946C-630C-423C-A503-F7C17B006AE3Q43823700-C9840B21-2A69-474F-A5AF-CAFCC637D750Q43905798-087B66F6-5A23-4AFA-984B-E7187A3BFF09Q44193673-39405C77-63F8-4886-B7CA-7BF89D977AA6Q44542738-1913E79A-6B52-4E14-B855-6AF504721544Q45736369-90F6556C-A99A-4973-88AE-F62A7C3CD1F7Q45787884-5578C7D4-6A15-4918-B129-CFED4157FEA4Q45839764-1A64BB1B-CF92-4B0E-92A8-D909AC104BBDQ45880396-37AFA91E-4AB5-478A-9CA0-5FC886C34ADEQ46277645-ECF53EDE-1623-4ED5-B873-E5D616823147Q46321423-16A590B2-F4F0-4D97-8CD9-38EE5169BB81Q46505791-8F17A0F7-579D-4B35-90FB-609EEADA2C7EQ46599456-045053B1-B785-4D57-A1D6-1FABFC7B41B9Q46759408-F394E105-2A1E-4068-9D49-36A4809CEF10
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Argyro Syngelaki
@ast
Argyro Syngelaki
@en
Argyro Syngelaki
@es
Argyro Syngelaki
@nl
Argyro Syngelaki
@sl
type
label
Argyro Syngelaki
@ast
Argyro Syngelaki
@en
Argyro Syngelaki
@es
Argyro Syngelaki
@nl
Argyro Syngelaki
@sl
prefLabel
Argyro Syngelaki
@ast
Argyro Syngelaki
@en
Argyro Syngelaki
@es
Argyro Syngelaki
@nl
Argyro Syngelaki
@sl
P106
P2038
Argyro_Syngelaki
P21
P31
P496
0000-0001-5856-6072